Piper Jaffray analyst Brooks West increased his price target on Boston Scientific to $26 from $22.50 after the company's beat and raise quarterly report, saying he believes the company has entered its next leg of growth driven by organic product launches and its recent acquisitions. The firm keeps an Overweight rating on Boston Scientific shares.
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here